킴스온라인

최근 해외학술대회의 주요 발표내용을 제공합니다.

컨퍼런스 커버리지

International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2025 (WCLC 2025)

06 September - 09 September, 2025, Spain

Add-on ivonescimab nearly halves risk of progression, death in EGFR+ NSCLC

2025-10-01

Results from the phase III HARMONi trial presented at WCLC 2025 show that adding ivonescimab to chemotherapy prolongs progression-free survival (PFS) in patients with advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs).
FLAURA2: Osimertinib-chemo prolongs OS by 4 years in EGFRm NSCLC

2025-10-01

In the planned final overall survival (OS) analysis of the FLAURA2 trial, first-line (1L) osimertinib plus chemotherapy significantly improved OS compared with osimertinib alone in EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC), supporting osimertinib as the backbone treatment in this setting.

주요메뉴